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The opening of mitochondrial permeability transition pore (mPTP) is a major cause of cell death in ischemia reperfusion injury.
Based on our pilot experiments, plant natural product formononetin enhanced the survival of rat cardiomyocyte H9c2 cells
during oxygen glucose deprivation (OGD) and reoxygenation. For mechanistic studies, we focused on two major cellular factors,
namely, reactive oxygen species (ROS) and glycogen synthase kinase 3𝛽 (GSK-3𝛽), in the regulation of mPTP opening. We found
that formononetin suppressed the formation of ROS and superoxide in a concentration-dependent manner. Formononetin also
rescued OGD/reoxygenation-induced loss of mitochondrial membrane integrity. Further studies suggested that formononetin
induced Akt activation and GSK-3𝛽 (Ser9) phosphorylation, thereby reducing GSK-3𝛽 activity towards mPTP opening. PI3K
and PKC inhibitors abolished the effects of formononetin on mPTP opening and GSK-3𝛽 phosphorylation. Immunoprecipitation
experiments further revealed that formononetin increased the binding of phosphor-GSK-3𝛽 to adenine nucleotide translocase
(ANT) while it disrupted the complex of ANT with cyclophilin D. Moreover, immunofluorescence revealed that phospho-GSK-
3𝛽 (Ser9) was mainly deposited in the space between mitochondria and cell nucleus. Collectively, these results indicated that
formononetin protected cardiomyocytes from OGD/reoxygenation injury via inhibiting ROS formation and promoting GSK-3𝛽
phosphorylation.
1. Introduction
Acute myocardial infarction (AMI) is a leading cause of
human death worldwide [1]. Timely reperfusion effectively
reduces short-term mortality in early-reperfusion phase [2].
One of the on-going issues is that reperfusion itself leads to
additional injury, causing all forms of cell death and con-
tractile dysfunction of surviving cells [3]. The mitochondrial
permeability transition pore (mPTP) is implicated in the
pathogenesis of myocardial ischemia-reperfusion injury [4].
Ischemia induces the close of mPTP, whereas reperfusion
promotes the mPTP opening [5]. Thus, control of mPTP
opening at the early reperfusion is important to protect the
heart against reperfusion injury [6]. Among various regula-
tors of mPTP opening, glycogen synthase kinase 3𝛽 (GSK-
3𝛽) is a constitutively active serine or threonine protein
kinase [7]. GSK-3𝛽 stimulates themPTPopening and thereby
induces mitochondrial dysfunctions in myocardial ischemia
reperfusion [8]. The enzymatic activity of GSK-3𝛽 is regu-
lated by phosphorylation. Phosphorylation at tyrosine 216
increases the activity, whereas phosphorylation at serine 9
significantly decreases the enzymatic activity of GSK-3𝛽
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Figure 1: Formononetin protected cardiomyocyte H9c2 cells
against OGD/reoxygenation injury. (a) Chemical structure of for-
mononetin. (b) Effect of formononetin on the cell viability of H9c2
cells under normal or OGD/reoxygenation condition. H9c2 cells
were treated with formononetin at various concentrations either
under normal condition for 24 h (Normal) or subjected to OGD for
8 h followed by reoxygenation for 16 h (OGD/R). The cell viability
was determined by MTT assay. The values represent mean ± SD
(𝑛 = 5). ##𝑝 < 0.01 (OGD/R versus Normal); ∗∗𝑝 < 0.01 (drug
versus OGD/R).
[7]. Moreover, phospho-GSK-3𝛽 (Ser9) suppresses pore for-
mation via interacting with adenine nucleotide translocase
(ANT), a major component of mPTP [9]. These results
highlight the importance of mPTP dynamics in myocardial
ischemia reperfusion injury.
Medicinal plants such as Radix Astragali are widely used
to treat cardiovascular diseases in traditional Chinese medi-
cine [10, 11]. As a major isoflavone compound from Radix
Astragali, formononetin bearing the structure shown in
Figure 1(a) exhibits a wide range of pharmacological prop-
erties such as anticancer [12, 13], anti-inflammatory [14],
antioxidant [15], antiviral [16], neuroprotective activities [17,
18], and wound healing [19]. However, little is known about
the molecular mechanisms underlying the cardioprotective
potential of formononetin within the context of myocardial
infarction.
In the present study, we initially discovered that for-
mononetin enhanced the survival of rat cardiomyocyte H9c2
cells during oxygen glucose deprivation (OGD) and reoxy-
genation. We hypothesize that formononetin may protect
cardiomyocytes against ischemia reperfusion injury by pre-
venting mPTP opening.We focused on the role of GSK-3𝛽 in
the regulation of mPTP opening in H9c2 cells. We further
examined the effects of formononetin on reactive oxygen
species (ROS), PI3K/Akt, and PKC.
2. Materials and Methods
2.1. Materials and Regents. Formononetin was obtained from
Yick-Vic Chemicals & Pharmaceuticals Ltd, (Hong Kong).
Antibodies for GSK-3𝛽 and adenine nucleotide translo-
case (ANT) were purchased from Santa Cruz Biotechnol-
ogy (Santa Cruz, CA, USA). Antibodies against phospho-
GSK-3𝛽 (Ser9), glyceraldehydes-3-phosphate dehydrogenase
(GAPDH), Akt, and phospho-Akt were obtained from Cell
Signaling Technology (Boston,MA,USA). AnticyclophilinD
(anti-Cyp-D) was purchased from Thermo Fisher Scientific
Inc. (Waltham, MA, USA). Alexa Fluor 594-conjugated goat
anti-rabbit IgG secondary antibody and Alexa Fluor 488-
conjugated goat anti-mouse IgG secondary antibody were
obtained from Invitrogen (Carlsbad, CA, USA).
2.2. Cell Culture. Rat cardiomyocyte H9c2 cell line was
obtained from Shanghai Institute for Biological Sciences,
Chinese Academy of Science (Shanghai, China), and cul-
tured in Dulbecco’s modified Eagle’s medium (DMEM)
supplemented with 10% heat-inactivated fetal bovine serum
(Gibco/BRL, Gaithersburg, MD, USA), 2mM glutamine, and
100U/mL penicillin A/streptomycin at 37∘C in a humidified
incubator containing 5% CO
2
.
2.3. Measurement of ROS and Superoxide Production. H9c2
cells were seeded in 6-well plate at the density of 0.3 ×
105 cells/mL overnight. After 24 h incubation, the cells were
exposed to OGD condition for 8 h and subsequently treated
with formononetin at different concentrations under reoxy-
genation condition for 30min. For the detection of intra-
cellular ROS, the cells were stained with 5𝜇M of 2󸀠,7󸀠-
dichlorofluorescein-diacetate (DCFH2-DA) from Life Tech-
nologies (Grand Island, NY, USA) at 37∘C for 30min. On
the other hand, the intracellular superoxide ion was detected
with dihydroergotamine (DHE) from Invitrogen Molecular
Probes (Eugene, OR, USA) at 37∘C for 30min. After the
removal of excessive probes, the cells were imaged on a laser
scanning fluorescence microscope (Carl-Zeiss, Jena, Ger-
many). The results were expressed as a percentage of the
intracellular ROS or superoxide production in OGD/reoxy-
genation-treated cells based on the analysis using NIH Image
J software (http://imagej.nih.gov/ij/).
2.4. Imaging of Mitochondrial Membrane Integrity. Mito-
chondrial membrane integrity was detected by staining with
tetramethylrhodamine methyl ester (TMRM) and calcein-
AM as reported [20, 21]. Briefly, H9c2 cells were exposed
to OGD condition for 8 h and treated with formononetin
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(5 to 30 𝜇M) under reoxygenation condition for another
20min. H9c2 cells were incubated with 250 nM TMRM in
medium for 15min. For calcein-AM staining, the H9c2 cells
were loaded with 1𝜇M calcein-AM in the presences of 8mM
cobalt chloride for 30min. After the removal of excessive dye
by three washes with PBS, the cell monolayer was examined
and imaged under a fluorescence microscope (Carl-Zeiss,
Jena, Germany) through a 560 nm long-path filter.
2.5. Immunoprecipitation. Immunoprecipitation (IP) was
performed as previously described [9]. In brief, 500 𝜇g of
total cellular proteins from different treatment groups was
incubated with 1𝜇g primary antibodies against ANT and
phospho-GSK-3𝛽 for 1 h at 4∘C. The mixture was incubated
with 20𝜇L of protein A/G PLUS-agarose slurry (Santa Cruz,
CA, USA) at 4∘C overnight. The samples were subsequently
centrifuged at 2500 rpm for 5min at 4∘C. The precipitations
were recovered and washed with PBS buffer for 3 times.
Finally, the pellets were dissolved in 60 𝜇L of 1x electrophore-
sis sample buffer and boiled for 5min. Thirty microliters of
each sample was analyzed by Western blotting.
2.6. Western Blot Analysis. The cellular proteins were extracted
with ice-cold RIPA buffer according to the manufacturer’s
instructions (Sigma-Aldrich, St. Louis, MO, USA). In brief,
30 𝜇g of the cellular proteins was resolved in 10% SDS-PAGE
and subsequently transferred onto polyvinylidene difluo-
ride (PVDF) membrane (EMD Millipore, Billerica, MA,
USA). Following the incubation in 5% BSA in TBST (50mM
Tris-Cl, 150mM NaCl, 0.1% Tween-20, pH 7.6) at room
temperature for 2 h, the membranes were probed with the
primary antibodies against the indicated proteins (1 : 1,000
dilution) at 4∘C overnight. After three washes with TBST
buffer, the membranes were incubated with horseradish
peroxidase- (HRP-) conjugated secondary antibody (1 : 1,000
dilution) at 4∘C for 3 h and visualized by enhanced chemi-
luminescence (ECL) reaction reagents (GE Healthcare, Upp-
sala, Sweden).
2.7. Cell Immunofluorescence Imaging. H9c2 cells were seeded
on a glass slide at the density of 0.5 × 104 cells/slide. After
24 h incubation, the cells were exposed to OGD condition
for 8 h and treated with 30 𝜇M formononetin under reoxy-
genation condition for another 20 minutes. At the end of
treatment, H9c2 cells were fixed with 4% paraformaldehyde
for 30 minutes, permeabilized with 0.5% Triton X-100 for
20 minutes, and blocked with 5% normal goat serum in
PBS for 2 h at room temperature. Phospho-GSK-3𝛽 (Ser9)
and mitochondrial membrane protein Tom20 were probed
with specific primary antibodies overnight at 4∘C. After 5
washes with PBS, the slides were incubated in the secondary
antibodies (i.e., Alexa Fluor 594-conjugated goat anti-rabbit
IgG secondary antibody andAlexa Fluor 488-conjugated goat
anti-mouse IgG secondary antibody) for 90min at room
temperature. The cell nuclei were stained with DAPI. After
the removal of excessive fluorescence reagents, the cells were
imaged on a Zeiss fluorescence microscopy (Carl-Zeiss, Jena,
Germany).
2.8. Statistical Analysis. Theresults were presented asmeans±
SD from three independent experiments. The data were
compared by one-way analysis of variance (ANOVA), fol-
lowed by least significant difference (LSD) post hoc test
using IBM software SPSS version 20.0 (Amonk, NY, USA).
Differences with 𝑝 < 0.05 were considered as statistically
significant.
3. Results
3.1. Formononetin Enhanced the Survival of H9c2 Cells against
OGD/Reoxygenation Challenge. The effect of formononetin
on the viability of H9c2 cells was measured by standard
colorimetric MTT assay. Under normal conditions, for-
mononetin at the concentration of 30 𝜇M did not affect cell
viability over a period of 48 h. As shown in Figure 1(b),
however, the cell viability was reduced to 66.7 ± 6.13%
after 8 h of OGD and 16 h of reoxygenation. Interestingly,
formononetin markedly increased the cell viability against
OGD/reoxygenation-induced injury in a concentration-
dependent manner.
3.2. Inhibitory Effect of Formononetin on ROS and Superoxide
Production. The effect of formononetin on the intracellular
redox status was determined by detecting the intracellu-
lar H
2
O
2
and superoxide ion. Upon the introduction into
the cells, the nonpolar probe DCFH2-DA was converted
into the polar intermediate DCFH by cellular esterases
and further oxidized to highly fluorescent product 2󸀠,7󸀠-
dichlorofluorescein (DCF) by the intracellular H
2
O
2
and
other types of ROS. On the other hand, superoxide anion
reacts with DHE, generating a red fluorescent product 2-
hydroxyethidium (EOH). As shown in Figures 2(a) and 2(b),
OGD/reoxygenation dramatically increased the generation
of H
2
O
2
and superoxide ion in H9c2 cells. Based on the
fluorescence intensity, we estimated thatOGD/reoxygenation
increased H
2
O
2
level by 1.7-fold and also enhanced super-
oxide ion formation by 1.6-fold relative to the untreated
controls. However, formononetin attenuated the effects of
OGD/reoxygenation on the generation ofH
2
O
2
and superox-
ide ion in a concentration-dependentmanner. Formononetin
at 30 𝜇M reduced OGD/reoxygenation-induced production
of H
2
O
2
and superoxide ion down to 1.3-fold and 1.2-fold,
respectively.
3.3. Effect of Formononetin on Mitochondrial Membrane
Integrity. To determine the effect of formononetin on mito-
chondrial membrane integrity, a cell-permeant and cationic
dye TMRM was used to localize active mitochondria. As
shown in Figure 3(a), after exposure to OGD for 8 h and
reoxygenation for 20min, the capability of mitochondria to
sequester TMRM was markedly diminished to 74.2 ± 2.2%
relative to untreated control cells. Formononetin preserved
the sequestration of TMRM by active mitochondria in a
concentration-dependent manner. After the treatment with
30 𝜇M formononetin, H9c2 cells showed the recovery of
TMRM fluorescence to 97.9 ± 5.0% relative to untreated
control cells. Calcein-AM staining showed similar results as
shown in Figure 3(b).
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Figure 2: Effects of formononetin on ROS and superoxide production in cardiac H9c2 cells. H9c2 cells were treated with various
concentrations of formononetin under OGD and reoxygenation (OGD/R) condition. Accumulation of ROS and superoxide inH9c2 cells was
detected by probes DCFH2-DA and DHE, respectively. (a) Representative images and quantification of relative ROS levels. The intracellular
ROS level in H9c2 cells was calculated based on fluorescence intensity. The results were expressed as means ± SD (𝑛 = 3). ###𝑝 < 0.001
(OGD/R versus Normal); ∗𝑝 < 0.05; ∗∗∗𝑝 < 0.001 (drug versus OGD/R). Scale bar, 10𝜇m. (b) Representative images and quantification of
relative superoxide levels. The intracellular superoxide level in H9c2 cells was calculated based on fluorescence intensity. The fluorescence
images were analyzed with NIH Image J software (http://imagej.nih.gov/ij/). The results were expressed as means ± SD (𝑛 = 3). ###𝑝 < 0.001
(OGD/R versus Normal); ∗𝑝 < 0.05; ∗∗∗𝑝 < 0.001 (drug versus OGD/R). Scale bar, 10𝜇m.
3.4. Effects of Formononetin on Akt and GSK-3𝛽 Phospho-
rylation. To discover the potential mechanisms, we first
examined the effects of formononetin on the phosphorylation
of Akt and GSK-3𝛽, especially the phosphorylation of GSK-
3𝛽 at Ser9. As shown in Figure 3(c), formononetin at the
concentrations (5–30𝜇M) induced the phosphorylation of
Akt and GSK-3𝛽 at Ser9 in a concentration-dependent man-
ner. We further verified the effects of formononetin on the
phosphorylation of Akt and GSK-3𝛽 at Ser9 in the cells after
exposure to OGD and reoxygenation condition. As shown
in Figure 3(d), the levels of phospho-Akt and phospho-GSK-
3𝛽 (Ser9) were suppressed under OGD/reoxygenation condi-
tion. However, formononetin increased Akt phosphorylation
against OGD/reoxygenation stimulation in a concentration-
dependent manner. Interestingly, formononetin even at the
concentration of 5𝜇Meffectively reversed the loss of GSK-3𝛽
phosphorylation against OGD/reoxygenation challenge.
3.5. Formononetin Activated Akt and PKC to Preserve
Mitochondrial Integrity. To understand how formononetin
induces the phosphorylation of GSK-3𝛽 at Ser9, following
OGD/reoxygenation challenge, we treated the cells with
formononetin in combination with PI3K inhibitor LY294002
(LY), PKC inhibitor GF109203X (GF), and ERK 1/2 inhibitor
PD98059 (PD). As shown in Figure 4(a), PI3K inhibitor
LY and PKC inhibitor GF almost abolished the stimulatory
effect of formononetin on the phosphorylation of GSK-3𝛽
at Ser9, whereas ERK1/2 inhibitor did not show any activity
against formononetin-induced formation of phospho-GSK-
3𝛽 (Ser9). Supportively, PI3K inhibitor LY and PKC inhibitor
GF effectively antagonized the effects of formononetin on
mitochondrial retention of TMRM and calcein-AM against
OGD/reoxygenation damage (Figures 4(b) and 4(c)).
3.6. Formononetin Stimulated the Binding of p-GSK-3𝛽 to
ANT in mPTP. To verify the effect of formononetin on the
mPTP opening, we examined the formation of protein
complex between two main mPTP components ANT and
Cyp-D. Following immunoprecipitation with anti-ANT
antibody, we analyzed the presence of ANT and Cyp-D by
Oxidative Medicine and Cellular Longevity 5
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Figure 3: Effects of formononetin on mitochondrial membrane integrity and phosphorylation of Akt and GSK-3𝛽. (a) Fluorescence images
and quantification of TMRM sequestration in mitochondria. H9c2 cells were treated with formononetin (5, 10, and 30 𝜇M) under normal or
OGD and reoxygenation condition and stained with TMRM. TMRMfluorescence intensity was determined by NIH image J software. Results
are presented as means ± SD (𝑛 = 3). ##𝑝 < 0.01 (OGD/R versus normal); ∗𝑝 < 0.05, ∗∗𝑝 < 0.01 (drug versus OGD/R). Scale bar, 10𝜇m.
(b) Fluorescence images and quantification of calcein sequestration in mitochondria. H9c2 cells were treated similarly as described in (a)
and stained with calcein-AM. Calcein fluorescence intensity was determined by NIH image J software. Results are presented as means ±
SD (𝑛 = 3). ###𝑝 < 0.001 (OGD/R versus normal); ∗∗∗𝑝 < 0.001 (drug versus OGD/R). Scale bar, 10𝜇m. (c) Western blot analysis and
quantification of phosphorylation of GSK-3𝛽 and Akt in response to formononetin. After the treatment with formononetin (5, 10, and 30 𝜇M)
under normal condition, H9c2 cells were lysed and subsequently analyzed for phosphorylation of GSK-3𝛽 (Ser9) and Akt byWestern blotting
using specific antibodies. Western blots were quantified by a densitometric method. Results are presented as means ± SD (𝑛 = 3). ∗𝑝 <
0.05, ∗∗𝑝 < 0.01 (drug versus control). (d) Western blot analysis and quantification of phosphorylation of GSK-3𝛽 and Akt in response
to formononetin under normal or OGD/R condition. After the treatment with formononetin (5, 10, and 30 𝜇M) under normal or OGD/R
condition, H9c2 cells were lysed and subsequently analyzed for phosphorylation of GSK-3𝛽 (Ser9) and Akt byWestern blotting using specific
antibodies. Western blots were quantified by a densitometric method. Results are presented as means ± SD (𝑛 = 3). ∗𝑝 < 0.05; ∗∗𝑝 < 0.01
(drugs versus control and drugs versus OGD/R).
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Figure 4: Roles of PI3K, ERK1/2, and PKC in the regulation of GSK-3𝛽 phosphorylation and mitochondrial membrane integrity by
formononetin. (a) Western blot analysis and quantification of GSK-3𝛽 phosphorylation. After the treatment with formononetin ± kinase
inhibitors, H9c2 cells were lysed and analyzed for GSK-3𝛽 phosphorylation at Ser9 by Western blotting using specific antibodies. Western
blots were determined by a densitometric method. Results are presented as means ± SD (𝑛 = 3). ##𝑝 < 0.01 (drug versus OGD/R);
∗𝑝 < 0.05, ∗∗𝑝 < 0.01 (drug + inhibitor versus drug). (b and c) Fluorescence images and quantification of TMRMand calcein sequestration in
mitochondria. After the treatment with formononetin ± kinase inhibitors under OGD and reoxygenation condition, H9c2 cells were stained
with TMRM and calcein-AM and imaged under a fluorescence microscope (Carl-Zeiss, Jena, Germany). TMRM and calcein fluorescence
intensity were quantified by a densitometric method. ##𝑝 < 0.001 (drug versus OGD/R), ∗𝑝 < 0.05 (drug + inhibitor versus drug). LY, PI3K
inhibitor LY294002; GF, PKC inhibitor GF109203X; PD, ERK 1/2 inhibitor PD98059. Scale bar, 10𝜇m.
Western blotting with specific antibodies. As shown in Fig-
ure 5(a), OGD/reoxygenation increased the formation of
ANT-Cyp-D complex, whereas formononetin diminished
OGD/reoxygenation-induced formation of ANT-Cyp-D
complex. On the other hand, we performed immunopre-
cipitation with anti-phospho-GSK-3𝛽 (Ser9) antibody and
subsequently analyzed the presence of ANT and phospho-
GSK-3𝛽 (Ser9) by Western blotting with specific antibodies.
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Figure 5: Effects of formononetin on the formation of ANT-Cyp-D complex and the binding of phospho-GSK-3𝛽 (Ser9) to ANT. (a)
Immunoprecipitation with antibody against ANT. After the treatment with formononetin under OGD and reoxygenation condition, H9c2
cells were lysed for immunoprecipitation (IP) with antibody against ANT. The pull-down materials were analyzed by immunoblotting (IB)
with antibodies against ANT and Cyp-D. (b) Immunoprecipitation with antibody against phospho-GSK-3𝛽 (Ser9). After the treatment
with formononetin under OGD and reoxygenation condition, H9c2 cells were lysed for immunoprecipitation (IP) with antibody against
phospho-GSK-3𝛽 (Ser9). The pull-down materials were analyzed by immunoblotting (IB) with antibodies against ANT and phospho-GSK-
3𝛽 (Ser9). (c) Immunofluorescence imaging of the intracellular phospho-GSK-3𝛽 (Ser9). After the treatment with formononetin under OGD
and reoxygenation condition, H9c2 cells were probed with antibody against phospho-GSK-3𝛽 (Ser9) and mitochondrial membrane protein
Tom20 and subsequently detected by fluorophore-labelled secondary antibodies, phospho-GSK-3𝛽 (Ser9) (RED), and Tom20 (GREEN),
respectively. The cell nuclei were indicated by DAPI staining. The images were captured under a fluorescence microscope (Carl-Zeiss, Jena,
Germany). Scale bar, 10 𝜇m.
We found that formononetinmarkedly increased the binding
of phospho-GSK-3𝛽 (Ser9) to ANT (Figure 5(b)).
The binding of phospho-GSK-3𝛽 (Ser9) tomitochondrial
membrane was further characterized by immunofluores-
cence staining. After 8 h ofOGD,H9c2 cells were treatedwith
30 𝜇M formononetin or equal volume of PBS under reoxy-
genation condition for 20min. The intracellular phospho-
GSK-3𝛽 (Ser9) was sequentially stained by specific antibody
and Alexa Fluor 594-conjugated goat anti-rabbit IgG sec-
ondary antibody. Mitochondria were indicated by sequential
staining of Tom20 with anti-Tom20 and Alexa Fluor 488-
conjugated goat anti-mouse IgG secondary antibody. DAPI
was used to visualize the cell nuclei. As shown in Figure 5(c),
formononetin dramatically increased the localization of
phospho-GSK-3𝛽 (Ser9) in mitochondria in close proximity
to the cell nucleus.
4. Discussion
Reperfusion of ischemic hearts is the main cause of the
opening ofmPTP, leading to the dysfunction ofmitochondria
[22]. The present study investigated that the effects of plant
natural product formononetin on the mPTP opening in an
in vitro OGD/reoxygenation-induced cell model of ischemia
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reperfusion injury. Following OGD challenge, we mimicked
reperfusion by incubating the cells with drugs under reoxy-
genation condition as previously described [23]. We discov-
ered that formononetin could enhance the survival of H9c2
cells and inhibit the mPTP opening through the potential
mechanisms involving the inhibition of ROS production
and Akt- and PKC-mediated phosphorylation of GSK-3𝛽 at
Ser9.
Formononetin, a major isoflavone from Radix Astragali,
was recently found to significantly reduce the infracted
volume and the brain water accumulation in a rat model of
ischemia-reperfusion injury via the activation of PI3K/Akt
signaling pathway [17]. Sulphonated formononetin also
showed cardioprotective effect on acute myocardial infarc-
tion in rats possibly by regulating energy metabolism in
cardiac mitochondria [24]. Inhibition of mPTP opening was
recently suggested as a potential therapeutic target for the
development of new cardioprotective drugs against myocar-
dial infarction [25, 26].These results stimulated us to explore
whether formononetin could exhibit cardioprotective effects
by regulating mPTP opening. In this study, we focused on
the effects of formononetin onOGD/Reoxygenation-induced
disruption of mitochondrial membrane integrity and the
underlying mechanisms. We first verified that formononetin
could effectively suppress the overproduction of ROS and
superoxide ion afterOGD/reoxygenation challenge.We char-
acterized the effects of formononetin on the phosphorylation
of GSK-3𝛽 (Ser9). Phosphorylation of GSK-3𝛽 at Ser9 causes
the reduction of GSK-3𝛽 activity [27]. Inactivation of GSK-
3𝛽 is known to modulate the mPTP opening, conferring
cardioprotection during ischemic preconditioning and post-
conditioning [9, 28].
In the present study, we found that formononetin
markedly induced the phosphorylation of GSK-3𝛽 at Ser9
in a concentration-dependent manner. Presumably, for-
mononetin could inactivate the enzymatic role of GSK-
3𝛽 in cardiac H9c2 cells. Importantly, formononetin could
recover the loss of phospho-GSK-3𝛽 (Ser9) formation against
OGD/Reoxygenation challenge. To elucidate themechanisms
bywhich formononetin stimulates the formation of phospho-
GSK-3𝛽 (Ser9), we explored the roles of the PI3K/Akt and
PKCpathways. It was previously demonstrated that PI3K/Akt
and PKC directly phosphorylated GSK-3𝛽 at Ser9 [29].
Another recent study reported that formononetin protected
cerebra against ischemia/reperfusion injury via the activation
of PI3K/Akt signaling pathway [17]. Indeed, formononetin
induced the activation of Akt in a concentration-dependent
manner. Formononetin at the concentration of 30𝜇M
achieved the most effective induction of Akt activation. On
the other hand, formononetin at the concentration of 5𝜇M
already strongly promoted the formation of of phospho-GSK-
3𝛽 (Ser9). Thus, we employed specific kinase inhibitors to
profile the actions of Akt, ERK1/2, and PKC on the phos-
phorylation of GSK-3𝛽 at Ser9. Consequently, we discovered
that both Akt and PKC contributed to the phosphorylation
of GSK-3𝛽 at Ser9. Importantly, PI3K inhibitor LY294002
and PKC inhibitor GF109203X not only antagonized the
stimulatory effects of formononetin on the phosphorylation
of GSK-3𝛽 at Ser9 but also attenuated the protective effects of
formononetin on mitochondrial membrane integrity. These
results highlight that formononetinmaymaintain mitochon-
drial membrane integrity via inducing the phosphorylation
of GSK-3𝛽 at Ser9 through Akt- and PKC-dependent mecha-
nisms. We further demonstrated that formononetin induced
the disassociation of ANT-Cyp-D complex and promoted
the binding of phospho-GSK-3𝛽 (Ser9) to ANT. Moreover,
GSK-3𝛽 is a multifunctional enzyme that regulates several
cellular functions and transcription factors [30]. Nuclear
GSK-3𝛽 level is markedly increased prior to the activation of
the caspase cascade leading to apoptosis [31]. Interestingly,
our immunofluorescence analysis suggested that phospho-
GSK-3𝛽 (Ser9) might be deposited in mitochondria in close
proximity to the cell nucleus. The deposition of p-GSK-3𝛽
at the interface between mitochondria and cell nucleus may
limit the flux of ROS into cell nucleus and thereby suppress
cell apoptosis.
The mPTP opening may be regulated by posttranslo-
cational modification of Cyp-D and physical interaction
of Cyp-D with matrix proteins (e.g., p53, PPAR alpha)
[32]. It was recently reported that active GSK-3𝛽 could
phosphorylate Cyp-D and stimulate the opening of mPTP
[33]. Conversely, the suppression of GSK-3𝛽 resulted in the
inhibition of mPTP opening by attenuating the phospho-
rylation of Cyp-D in murine tubular epithelial cells [34].
In the present study, we found that formononetin could
induce GSK-3𝛽 phosphorylation at Ser9, causing the loss
of GSK-3𝛽 enzyme activity. Taken together, it is possible
that formononetin inhibited the phosphorylation of Cyp-D,
contributing to the inhibition of mPTP opening. In addition
to ANT, Cyp-D interacts with several other proteins (e.g.,
p53) to induce PTP opening and necrosis. Tumor suppressor
protein p53 is accumulated in the mitochondrial matrix and
interacts with Cyp-D during ischemia/reperfusion injury.
Conversely, the reduction of p53 is protective during stroke
due to the loss of Cyp-D and p53 complex [35]. Oxidative
stress could induce the formation of Cyp-D-PPAR𝛼 complex
in cardiomyocytes, while the disruption of Cyp-D-PPAR𝛼
complex by metformin could protect cardiomyocytes against
oxidative stress-induced cell death [36]. Moreover, recent
studies provided new evidences to support the roles of
Cyp-D and F1F0-ATPase in the control of mPTP open-
ing. F1F0-ATPase mainly affects mitochondrial ATP storage
[37]. Suppression of the F1F0-ATPase in the mitochondrial
matrix could conserve energy during the cardioprotection
intervention of Bcl-2 or GSK-3𝛽 inhibitors, although GSK-
3𝛽 inhibitors could not affect the activity of F1F0-ATPase
[38]. Others also demonstrated a central role for mitochon-
drial GSK-3𝛽 but not F1F0-ATPase as target of PKC𝜉 to
limit I/R damage [39]. In the present study, we discovered
that formononetin could disrupt the interaction between
ANT and Cyp-D. The disassociation of ANT from Cyp-
D likely indicates that formononetin dismantles the mPTP
complex via stimulating GSK-3𝛽 phosphorylation at Ser9
and inhibiting the enzymatic activity of GSK-3𝛽. Further
work is required to clarify (1) whether formononetin affects
the interactions of Cyp-D with p53 and PPAR𝛼 and (2)
whether formononetin affects the activity of mitochondrial
F1F0-ATPase.
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Figure 6: Proposed mechanism underlying the cardioprotective
effect of formononetin. Formononetin activates PI3K/Akt and PKC
signaling pathways and subsequently induces the phosphorylation
of GSK-3𝛽 at Ser9. The phosphorylation of GSK-3𝛽 at Ser9 leads
to the inactivation of GSK-3𝛽 in the opening of mPTP. On the
other hand, phospho-GSK-3𝛽 (Ser9) migrates towards mitochon-
dria and binds to ANT, causing the disassociation of the mPTP
complex involving ANT, Cyp-D, VDAC, and HKII. Formononetin
also inhibits the overproduction of ROS and superoxide, possi-
bly reducing the oxidative damage of mitochondria in cardiomy-
ocytes.
In addition, it was reported that the phosphorylation
of GSK-3𝛽 at Ser9 suppressed mPTP opening via inter-
acting with and phosphorylating VDAC [40]. Activated
GSK-3𝛽 also phosphorylates VDAC and thereby disrupts
the binding of hexokinase II to mitochondrial components
[41]. However, the exact role of VDAC in the regulation
of mPTP opening remains elusive. The results from our
study defined that formononetin inhibited the activity of
GSK-3𝛽 by Ser9 phosphorylation and did not exclude the
interactions of GSK-3𝛽 and phospho-GSK-3𝛽 (Ser9) with
VDAC.
In summary, the results from the present study sug-
gest that formononetin may protect cardiomyocytes against
ischemia reperfusion injury by inhibiting themPTP opening.
The potential underlying mechanisms could be outlined in
Figure 6. Formononetin may initiate its actions by suppress-
ing the production of ROS and superoxide ion and activating
Akt and PKC pathways. Upon activation, Akt and PKC
subsequently phosphorylate GSK-3𝛽 at Ser9, leading to direct
inhibition of GSK-3𝛽 activity towards the mPTP opening
and the disruption of the protein complex involving ANT
and Cyp-D. Ultimately, formononetin attenuated the mPTP
opening and maintained mitochondrial membrane integrity.
Thus, formononetin may serve as a useful lead compound
for future development of new cardioprotective drugs against
acute myocardial infarction.
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